

Development of candidate compounds as PPARgamma/AMPK dual agonists for treatment of diabetes

dalimbiotech
dalimbiotech

METABOLIC	Candidate
Product Type	Small molecules
Indication	Diabetes & Metabolic diseases
Target	PPAR γ , AMPK
MoA(Mechanism of Action)	Activating PPAR and AMPK by direct binding to PPAR and AMPK → improves insulin sensitivity
Competitiveness	<ul style="list-style-type: none"> - Not to induce obesity through selective PPARγ activation and/or AMPK activation. - To activate AMPK in all tissues as a direct AMPK agonist
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.